Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
This study has been completed.
Study NCT00077805 Information provided by Sanofi-Aventis
First Received: February 12, 2004 Last Updated: October 14, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Ischemic Stroke
Additional conditions recognized in this trial
Cerebral Infarction
Ischemia
Stroke
Thromboembolism
Venous Thromboembolism
More general conditions related to this trial
Brain Diseases
Brain Infarction
Brain Ischemia
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Embolism and Thrombosis
Nervous System Diseases
Pathologic Processes
Thrombosis
Vascular Diseases
Interventions listed in this trial
Enoxaparin sodium
Additional drug interventions recognized in this trial
Enoxaparin
Heparin, Low-Molecular-Weight
More general drug interventions related to this trial
Anticoagulants
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Sanofi-Aventis
Back to top of Main Content
